Navigation Links
One-year results from Horizons-AMI trial reported at TCT 2009
Date:9/21/2009

death.

High-Risk Patients A related study from Italy looked at who gained the greatest benefit of bivalirudin monotherapy (BIV) in the treatment of STEMI patients undergoing primary PCI and found the patient cohort that gained the most was the highest risk subject population. According to the lead researcher, Guido Parodi, MD, PhD, FESC, Associate Chief Invasive Cardiology, Careggi Hospital, University of Florence (Florence, Italy), "It was completely contrary to our expectations. In particular, we found that in those patients at the highest risk for dying at one year, randomization to bivalirudin instead of heparin plus a GPIIb/IIIa antagonist appeared to provide the greatest mortality benefit."

In this substudy of the HORIZONS-AMI trial, bivalirudin monotherapy (BIV) was compared to unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI). BIV resulted in a reduction of major bleeding, a decrease in 30-day and 1-year mortality and enhanced freedom from net adverse clinical events (NACE) in patients with STEMI undergoing primary PCI. Whether the beneficial effects of BIV are related to patient risk category is not known.

In HORIZONS-AMI, 3,602 STEMI patients were treated within 12 hours of symptom onset and underwent primary PCI to BIV monotherapy vs. UFH+GPI. Patients were classified as low (score from 0 to 2), medium (score from 3 to 5), and high risk (score >5) according to the CADILLAC Risk Score based on 7 clinical variables (baseline EF<40%, renal insufficiency, Killip class ≥ 2, final TIMI flow< 3, age > 65, anemia, and 3V disease).

Among 2,530 evaluable HORIZONS-AMI trial patients, 1,522 pts (60%) were classified as low risk, 531 patients (21%) were classified as medium risk and 477 patients (19%) were classified as high risk.

Among high risk patients, there was a significantly lower rate of myocardial infarction (3.6% vs. 7.9%) and non-significant trends toward less stent thrombosis (2.
'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. 132 Members of Congress Urge One-Year Delay in Controversial Medicare Bidding Program for Home Medical Equipment
2. INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
3. New type of sirolimus-eluting stent demonstrates superior results
4. Details Emerge About Approach, Results of First US Face Transplant
5. Instrumentation Laboratory Announces Passion & Results Award Winners
6. Bioniche Reports Fiscal 2009 Year-End Results
7. Results of Ongoing Testing Show Air Quality is Safe Near Schools in Beaver and Erie Counties in Pennsylvania
8. Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
9. PRO-DEX, INC. Announces Fiscal 2009 Fourth Quarter and Full-year Results
10. Immucor to Announce Fiscal First Quarter Financial Results on Thursday, October 1, 2009
11. Neogen Corporation Announces 1st Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
(Date:10/30/2014)... October 30, 2014 Graphics, coding, typography ... synonymous with the craft of web design and require ... Yet a simpler solution to create a website can ... videos, contact information, customer reviews and Facebook posts all ... "It is the next evolution of how a business ...
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... Thompson HealthDay Reporter WEDNESDAY, ... Liberia -- one of three West African nations ravaged by ... said Wednesday. Dr. Bruce Aylward, WHO,s assistant director general, ... in Liberia and no increase in laboratory-confirmed cases. He said ... the epidemic may be making some progress, The New ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... , , WICHITA, Kan., ... public that late-term abortionist LeRoy Carhart will not be granted a transfer ... hours after Operation Rescue launched a pet i ... that Wesley Medical Center deny late-term abortionist LeRoy Carhart hospital or transfer ...
... RIVER EDGE, N.J., Aug. 14 Nephros, Inc. (OTC Bulletin Board: NEPH) announced today ... Recent Highlights , , , ... , Issued four new patents , ... , "2009 has continued to be a productive year for Nephros," said ...
... , , , , ... US: ADL), a U.S.-based pharmaceutical company with major operations in China, ... Rule 12b-25 of the Securities Exchange Act of 1934, as amended, ... Report on Form 10-Q for the second quarter ended June 30, ...
... , Visit by Lung Cancer ... , WASHINGTON, Aug. 14 /PRNewswire-USNewswire/ -- Today, Lung ... has signed on as a cosponsor of a bill to establish the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , , ...
... effective with few side effects, study finds , FRIDAY, ... called Levadex is an effective treatment for migraines, according ... trial, conducted at the Jefferson Headache Center at Thomas ... who took the drug had greater relief from symptoms ...
... , WASHINGTON, Aug. 14 The Sixth ... of an Ohio law strictly regulating the provision of the dangerous ... CEO and President of Americans United for Life, stated, "This is ... providers have readily admitted that they administer RU-486 in violation of ...
Cached Medicine News:Health News:Operation Rescue: Wesley Medical Center Promises To Keep Carhart, Abortions Out 2Health News:Nephros Reports 2009 Second Quarter Financial Results 2Health News:Nephros Reports 2009 Second Quarter Financial Results 3Health News:Nephros Reports 2009 Second Quarter Financial Results 4Health News:Nephros Reports 2009 Second Quarter Financial Results 5Health News:AMDL Inc. Files Notification of Late Filing for Form 10-Q 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 2Health News:Senator Ben Nelson (D-NE) Joins as Co-Sponsor of Lung Cancer Mortality Reduction Act 3Health News:Americans United for Life Applauds Decision Protecting Women From Dangers of RU-486 2
(Date:10/30/2014)... VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ ... accelerated dramatically as a result of government initiatives ... time - healthcare providers have invested over the ... the heart of health IT, and U.S. clinicians ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
Breaking Medicine Technology:Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... Ltd. (Amex:,SVA), a leading provider of biopharmaceutical products ... trials for its pandemic influenza,vaccines. Sinovac received approval ... Drug Administration (SFDA) to commence Phase Ib and ... inactivated vaccine and Phase I and,II trials of ...
... of Proprietary siRNA Molecule in Acute ... ... Inc., a,development-stage pharmaceutical company focused on discovering and,developing novel RNA interference-based ... its proprietary product,candidate, AKIi-5, a siRNA compound discovered and developed by ...
Cached Medicine Technology:Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
...
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
Medicine Products: